Most common causes of exacerbations of COPD.
1. Introduction
Chronic obstructive pulmonary disease (COPD) is a disease which is characterized by airway inflammation and progressive airflow limitation with poor reversibility. Patients with COPD can experience periods of acute deterioration, which are called exacerbations. There are different definitions for an acute exacerbation of COPD (AECOPD). A symptom reported AECOPD is defined solely based on a patient’s symptoms [1]. This is regardless of whether the patient seeks medical attention or receives treatment for the exacerbation. An event defined AECOPD requires a therapeutic intervention such as a change in COPD medications or a change in healthcare utilization [1]. Generally accepted is the definition as in the guidelines of the World Health Organization, US National Heart Lung and Blood Institute and Global Initiative for Chronic Obstructive Lung Disease (GOLD), which define an exacerbation as “an event in the natural course of the disease characterized by a change in the patient’s baseline dyspnoea, cough, and/or sputum that is beyond normal day-to-day variations, is acute in onset and may warrant a change in regular medication in a patient with COPD” [2]. Frequent exacerbations can result in a decreased health related quality of life [3], a decline in lung function [4], an increased risk of hospitalization [5] and an increase in mortality [6].
COPD and acute exacerbations of COPD (AECOPD) impose a burden on health care and society. It is estimated that COPD is the 4th leading cause of death worldwide and will be the 3rd leading cause of death in 2030 [7]. Along with increasing mortality rates, the loss in disability-adjusted life years (DALYs) also rises. By 2030 COPD will be the 5th leading cause of loss in DALYs globally, where it was only number 13 in 2004. Increasing health care costs will be the consequence of this trend. In the European Union COPD accounts for just over 3% of the total health care budget. In the USA, the direct and indirect costs for COPD are almost 50 billion USD. The majority of these costs are attributed to exacerbations [8]. The importance of exacerbations is reflected in the latest update of the GOLD report, in which the number of exacerbations in the preceding year is incorporated in the new classification of a patient with COPD [8]. In order to try to reduce the mortality, loss in DALYs and related costs and to lower the burden on society and health care, it is a goal to prevent and treat COPD and exacerbations of COPD. This chapter will give a concise overview of the background of AECOPD and the available tools for its treatment and prevention.
2. Epidemiology
The prevalence of COPD varies greatly per country and also within countries [9]. This heterogeneity can be contributed to not only differences in diagnostic methods and classification but also to smoking habits, population age, in- and outdoor air pollution, occupational exposure, prevalence of pulmonary tuberculosis, chronic asthma and socioeconomic status [10]. Prevalences of COPD have been reported varying from 0,2-37% [11, 12]. The prevalence of AECOPD is very difficult to determine since there is no generally agreed definition for an AECOPD (see above). Studies show that only 32-50% of symptom defined AECOPD are reported by patients to health care professionals [13, 14]. Although there is no reliable estimate of the prevalence of AECOPD, much is known about the occurrence of exacerbations. Research shows that exacerbations are more frequent in the winter season [15] and may occur clustered in time [16]. Exacerbations are also more frequent and severe as COPD severity increases [17]. Besides COPD severity, the history of exacerbations is also a good predictor of future exacerbations [17]. Furthermore, there is a strong correlation with symptoms of depression and recurrent exacerbations [18, 19].
3. Pathophysiology of COPD and AECOPD
COPD is the result of a chronic inflammation in the airways. The inflammation is initiated by chronic exposure to exogenic toxins (e.g. cigarette smoke) which is causing damage to the airway epithelium and is activating the innate immune system giving a rapid, nonspecific response [20, 21]. Of the innate immune response the neutrophillic inflammation is most prominent in COPD. The cells of the innate immune system activate the adaptive immune system, of which CD8+-cells, CD4+ Thelper1 cells and B-cells have an important role in COPD. This activation of the adaptive immune response is the beginning of a cascade which causes extensive chronic inflammation, oxidative stress and remodeling, resulting in destruction of alveolar space and deposition of connective tissue in the subepithelium and adventitium of the airway wall [22]. The degree of chronic inflammation in COPD correlates with the severity of airflow limitation. This is supported by a correlation which is seen between the severity of obstruction and presence of CD8+-cells and B-cells in the small conducting airways [22] and the presence of neutrophils in sputum [23]. Also, bacterial colonization is more frequently observed in patients with severe to very severe COPD, suggesting that bacterial colonization induces inflammation and contributes to the progression of COPD [24, 25]. The existence of the chronic inflammation and oxidative stress is supported by the presence of oxidants and numerous pro-inflammatory cytokines in the airways and serum. Compared to healthy controls, sputum specimens of patients with stable COPD and AECOPD show increased numbers of neutrophils and increased levels of pro-inflammatory cytokines like interleukin-6 (IL-6) and interleukin-8 (IL-8) [21, 23, 26-29]. During an AECOPD neutrophils, IL-6 and IL-8 are also increased in serum [27, 30, 31]. Interleukin-6 is a cytokine released during initial immune response by different cell types of the native immune system, like macrophages. It induces hepatic acute phase response during inflammation [32] which in turn increases production of C-reactive protein (CRP). Interleukin-6 is also a growth factor for T- and B-cells [33]. Interleuking-8 is released by a variety of cell types involved in inflammation, like endothelial cells, fibroblasts and monocytes [34]. It is a potent neutrophil chemotactic and activating factor [34]. The presence of the increased inflammation in serum both during stable state and AECOPD may be explained by the “overspill theory”, in which the local inflammatory processes in the lung “spill over” to the systemic circulation [35]. It is therefore thought that disease activity of COPD can be measured in serum by biomarkers. Exhaled breath condensate (EBC) components are thought to reflect the physiological state of lining fluid of the airways. It’s a non-invasive mean of obtaining information on oxidative stress and inflammation in the airways. Hydrogen peroxide (H2O2, a precursor of potent oxidants OH and HOCl) and 8-isoprostane (formed by the free radical peroxidation of arachidonic acid) are EBC oxidative stress biomarkers proven to be elevated in patients with COPD during stable state and during exacerbations [31, 36-38]. Heme-oxygenase-1 (HO-1) is an inducible catalyzer of the degradation of heme to biliverdin which is thought to provide protection from oxidative stress. It is decreased in ex-smokers with COPD compared to control subjects [39] but increased during severe exacerbations [29], in healthy smokers and current smokers with COPD [40].
4. Aetiology of AECOPD
4.1. Microbiology
There is a great variety in reported infectious causes of COPD exacerbations. It is of importance to determine, both for bacteria and viruses, whether the presence of the microbe is actually the cause of the exacerbation. Estimated is that about 50-78% of acute exacerbations of COPD are caused by respiratory infections [24, 27, 41, 42], in which the clinical presentation range from pneumonia to coryzal symptoms with dyspnea. Patients with AECOPD of proven infectious aetiology have a longer hospital stay and a greater decrease in FEV1 than patients with non-infective exacerbations [27].
4.2. Viral causes
In the past viruses have been an underestimated cause of AECOPD and the causative role of viruses in AECOPD is still not fully established. The observation that as well viral infections and exacerbations are seasonal does suggest that viruses have a role in AECOPD [15, 43]. Recently researchers deliberately exposed patients with COPD and healthy smokers to rhinoviruses and observed that this virus was able to cause an exacerbation in patients with COPD [44]. Detection of viruses by culture and by serology, where a second serum sample is also required, is less sensitive and more time consuming than PCR techniques, where only 1 sample is required. Because of the advanced PCR techniques in detecting viruses, the percentage of exacerbations they account for can also be overestimated. The presence of viral DNA or RNA does not implicate that the virus is the cause of an exacerbation as several studies reported patients with stable COPD to carry viruses with percentages varying from 12-19% [45, 46]. In exacerbations several studies have reported that viruses were detected in 20-56% of cases [24, 27, 41, 42, 46, 47]. In these studies rhinovirus, influenza virus and respiratory syncytial virus and were the most common isolated viruses. A more extensive overview can be found in table 1.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Human rhinovirus | |
Respiratory syncytial virus | |
Influenza virus | |
Parainfluenza virus | |
Human metapneuvirus | |
Coronavirus | |
Adenovirus | |
|
|
|
|
|
|
|
|
|
|
|
|
Sulphur dioxide (SO2) | |
Ozone (O3) | |
Nitrogen dioxide (NO2) | |
Particulate matter (PM2,5 , PM10) |
4.3. Bacterial causes
Bacteria as cause of AECOPD are reported from 30% [48] up to 55% [27, 49]. The most common bacterial pathogens are
4.4. Non-microbial causes
One tenth of AECOPD are due to environmental pollution, of which ozone, sulphur dioxide and nitrogen dioxide known and researched causes [53, 54]. Particulate matter (PM) is also related to increased admissions for COPD and other respiratory diseases [53, 55]. Particulate matter consists of a mixture of solid particles and liquid aerosols suspended in the air from natural sources, industrial activities and can also be traffic related [56]. Other possible, non-infectious causes may be left sided heart failure, change in environmental temperature, but about 30% of exacerbations are of unknown origin [6].
5. Clinical Presentation and Diagnosis
5.1. History
Patients with an AECOPD usually present with dyspnea, which may be acute but can also be a history of slowly progressive dyspnea. Coughing or sputum production may or may not be present. When expectorating sputum, it is important to assess whether sputum volume has increased and whether it is purulent (e.g. green). Purulent sputum is usually a sign of infection [57]. Fever or other signs of infection should be looked for. Hemoptysis may be present in case of a severe infection. Risk factors for atypical infections should be thought of.
5.2. Laboratory tests
Laboratory test can be performed if necessary. C-reactive protein as marker for inflammation can be performed. Additional laboratory tests can be performed depending on the differential diagnosis. If available, an arterial blood gas can be performed. Hypoxemia may be present and in more severe cases a patient can also retain CO2. Hypercapnia is defined as arterial blood gas CO2 (
5.3. Radiology
A chest X-ray is mainly useful for excluding other pathology like pneumothorax, pleural fluid, congestive heart failure or otherwise. It may reveal consolidations or other pathology. In the acute phase a chest CT-scan has no additive value in the tract of diagnosing an exacerbation of COPD. It can be performed if doubts exist about the presence of pulmonary embolisms as an explanation for dyspnea and/or desaturation. In a patient with recurrent airways infections a CT-thorax can be performed to investigate whether bronchiectasis is present.
5.4. Biomarkers
Biomarkers can be used as indicators of a physiological state in which a patient is or may become, it can help in diagnosis, aetiology and prognosis. In theory, biomarkers could be used to predict exacerbations, to determine if a patient has increased inflammation, to distinguish type of inflammation (bacterial or viral infection or otherwise) or to predict clinical outcome after an AECOPD.
Many biomarkers have been researched of which many of them are of little clinical use. At this moment the most important biomarkers in AECOPD are CRP, serum IL-6, 8-isoprostane, H2O2 and procalcitonin (ProCT). These biomarkers are closely related to oxidative stress and inflammation. C-reactive protein is momentarily the most widely used marker of inflammation in clinical practice.
In patients with frequent exacerbations, both CRP and serum IL-6 levels are increased during a stable phase but also during the recovery period of an AECOPD [58, 59] compared to patients with infrequent exacerbations. Interleukin-6 is a cytokine which is widely expressed and produced in the body, and is not specific to the lung. Serum IL-6 has no additional value above CRP in clinical decision making. Interleukin-6 levels in sputum may be of use to predict therapy response [58], although more research is needed before clinical decisions can be made based on this biomarker. Similarly, there is a lack of studies which investigate the use of exhaled biomarkers 8-isoporstane and H2O2 for clinical purposes. Procalcitonin may be a biomarker which can discriminate in aetiology of an exacerbation but may also be used as therapeutic response parameter. Procalcitonin is the precursor of calcitonin and is released in response to a bacterial infection by many tissues under stimulation of several cytokines. Procalcitonin levels are minimally raised in viral infections [60], making it a relative specific diagnostic tool for bacterial infections. Most research has been performed in patients with community acquired pneumonia (CAP) [61]. It is suggested that ProCT could become a useful tool in clinical decision making regarding antibiotic therapy. There have been several trials to assess the utility of ProCT in AECOPD. In general ProCT-guided antibiotic therapy compared to standard management in AECOPD showed no differences in death from any cause, rates of intensive care unit (ICU) admission for any reason, duration of ICU stay, improvement of symptoms, difference in the quality-of-life score, re-exacerbation and readmission [62]. Procalcitonin-guided antibiotic therapy showed reduction in antibiotic prescription [62] and in one study [63] also reduction in antibiotic therapy duration, which in turn decreases the patient’s exposure to antibiotics and related side effects, lowers the burden of antibiotic use and the risk of antimicrobial resistance. Procalcitonin is not yet being implemented in standard care though, as it is relatively expensive and there has been little to no research performed outside Europe.
6. Management
The treatment of an AECOPD consists of supportive therapy, maximal bronchodilation, steroids to reduce the inflammation and treatment of the cause.
6.1. Supportive therapy
Oxygen delivery is one of the first supportive therapies which can be provided for a patient. Oxygen saturation should be at least 90% though in some cases lower saturations may also be accepted. Too much oxygen may cause hypercapnia as the drive to breathe in some COPD patients may rely on arterial O2 pressure. Symptoms of acute hypercapnia are somnolence, headache, drowsiness, confusion, flushed skin or agitation. Physiotherapy during an admission for an AECOPD can prevent deterioration in skeletal muscle function and improve exercise capacity [64, 65]. Because an AECOPD is accompanied by an impaired energy balance due to a decreased dietary intake and an increased resting energy expenditure, nutritional support may also benefit the patient in terms of general well-being and prevention of muscle wasting [66-68].
6.2. Pharmacotherapy
An exacerbation is the result of increased inflammation causing increased flow limitation. Treatment should be directed towards controlling this exacerbated inflammation and maximizing bronchodilation. Short acting agents like salbutamol and ipratropium are mostly used for maximal bronchodilation, usually delivered by nebulizer. Many patients may not be able to generate the flows required to use other devices during an exacerbation. Corticosteroids have been proven to reduce time to recovery and treatment failure, increase FEV1 and arterial hypoxemia [8]. Treatment schemes have been reported varying from 30 mg prednisolone orally to 60 mg intravenous, ranging from 5 days to two weeks. Studies showed that there is no difference in clinical outcome if a patient is treated with oral steroids compared to parenteral steroids [69]. Antibiotic treatment can be initiated when a bacterial infection is suspected. With the Anthonisen criteria [70] one can decide whether antibiotic treatment is necessary or not. These criteria are derived from a randomized placebo-controlled crossover trial which has been performed in the ‘80s where patients with COPD exacerbations were treated with antibiotics or placebo. The cardinal symptoms of infection in this study were increased sputum volume and purulence in combination with increased dyspnea. An exacerbation with all the previous 3 symptoms is called a type 1 exacerbation; two out of three symptoms have to be present for a type 2 exacerbation; one out of three and at least one other “minor symptom” (see table 2) have to be present for it to be a type 3 exacerbation. Patients with type 1 and type 2 exacerbations are most likely to benefit from antibiotic therapy. In Spain a pilot study was performed with hospitalized patients with AECOPD, where antibiotic therapy was given to patients with self-reported purulent sputum and withheld in patients with non-purulent sputum [71]. There was no difference between the two groups in treatment failure on day 3, suggesting patient reported non-purulent sputum may be a valid criterion to withhold antibiotics [71]. A Dutch study showed that addition of doxycycline to the treatment regimen with glucocorticoids of a patient with an exacerbation was superior on day 10 but equivalent on day 30 in terms of clinical success and clinical cure compared to glucocorticoids alone, even in patients not showing signs of infection [72]. Most recently Spanish investigators performed a multicenter trial where they suggested that treatment of a mild to moderate exacerbation with amoxicillin/clavulanate, independent of glucocorticoids treatment, might give better clinical cure after 10 days compared to placebo [73]. In this study the median time to next exacerbation was also increased in patients receiving antibiotics compared to placebo. Unfortunately, because of recruitment problems this study did not reach the calculated amount of patients needed, so that definite conclusions cannot be made from the results of this study.
|
|
Type 1 | Increased dyspnea Increased sputum volume Increased sputum purulence |
Type 2 | Two symptoms of type 1 |
Type 3 | 1 of three symptoms of type 1, plus at least one of the following findings: - Upper respiratory infection (sore throat, nasal discharge) within the past 5 days - Fever without other cause - Increased wheezing - Increased cough - Increase in respiratory rate or heart rate by 20% as compared with baseline |
7. Prevention
Preventing exacerbations is an important treatment goal in COPD. There is a wide range of preventive measures which have proven to reduce exacerbation frequency or hospitalization in patients with AECOPD.
7.1. Supportive measures
Influenza vaccination and pneumococcal vaccination have both been researched as preventive measures for infection associated exacerbations. Current GOLD guidelines [8] advise influenza vaccination for patients with COPD. Pneumococcal vaccination is mainly advised for elderly patients with COPD. Investigation on this subject is ongoing. Of the non-pharmacologic interventions, pulmonary rehabilitation is the most effective in reducing hospital admissions and mortality and improving health-related quality of life in COPD patients who have recently suffered an exacerbation of COPD [74].
7.2. Long-acting bronchodilators
Long-acting bronchodilators can be divided in two groups: long acting muscarinic receptor antagonists (LAMAs) and long acting β-agonists (LABAs). Both have proven to show a positive effect on exacerbation reduction and improvement in quality of life [75-79]. An overview of the long-acting bronchodilators is given in table 3.
|
|
Formoterol | Tiotropium |
Arfomoterol | Glycopyrronium |
Salmeterol | |
Indacaterol |
Of the long-acting bronchodilators, indacaterol and glycopyrronium are the most recent additions for the treatment of COPD. Indacaterol is proven to be superior to formoterol, salmeterol and tiotropium in terms of use of rescue medication, dyspnoea score and health related quality of life. Compared to salmeterol and formoterol it is also superior in improving spirometry values. Indacaterol is non-inferior to tiotropium but when added to tiotropium therapy it is superior compared to tiotropium alone [80]. Indacaterol also lowers the risk of AECOPD compared to placebo [78, 81, 82]. Glycopyrronium has been approved in 2012 as therapy for COPD. It provides significant improvements in lung function, dyspnoea, health status, exacerbation frequency and rescue medication use versus placebo, and is comparable to tiotropium [83, 84]. The combination of glycopyrronium and indacaterol has shown superiority in bronchodilation compared to indacaterol alone [85]. Glycopyrronium has not been compared to other LABAs yet.
7.3. Inhalation corticosteroids
Inhalation corticosteroids (ICS) can be given to patients with high risk of exacerbations. In several studies ICS provided a reduction of symptoms (dyspnea, cough) and reduced the frequency of exacerbations [86-88]. The GOLD guidelines advise treatment for high exacerbation risk patients with few symptoms (group C) with a combination of ICS/LABA or a LAMA alone, or a combination of LABA and LAMA [8]. For high exacerbation risk patients who have many symptoms (group D) the same treatment is advised as for group C, also a combination of all three classes of inhalation drugs is possible [8].
7.4. Phosphodiesterase inhibitors
Currently, two phosphodiesterase inhibitors are available for the treatment of COPD: theophylline and roflumilast. Theophylline is a xanthine derivative which acts as a non-selective phosphodiesterase inhibitor. It has bronchodilator effects, improves symptoms and there is evidence that it can reduce exacerbations [89-91]. It is a drug which needs therapeutic window monitoring. It can interact with many drugs and can have toxic side effects which may be potentially dangerous, like cardiac arrhythmia. Therapy with theophyllines is not recommended if LABAs are available but can be used as add-on therapy [8]. Roflumilast is a selective phosphodiesterase-4 inhibitor. It increases prebronchodilator FEV1 and can reduce exacerbations in a selected group of patients with COPD [92, 93]. In all trials patients in the roflumilast group experienced more side effects in comparison to patients in the placebo groups. The side effects were mostly gastro-intestinal related (nausea, diarrhoea, weight loss) and headache. These adverse events were associated with increased patient withdrawal in the roflumilast groups. The design of the trials limits the generalizability of these results. The included COPD patients were required to have symptoms of chronic bronchitis and AECOPD in the past. More investigation is needed to determine the exact place of this medication in the treatment of AECOPD.
7.5. Macrolide antibiotics
Antibiotic prevention of exacerbations is a highly researched topic in COPD. The most promising class of antibiotics appear to be macrolides. In various chronic lung diseases they seem to have an immune modulatory function.
7.5.1. Proposed working mechanism
Much
7.5.2. Success of macrolides in chronic lung diseases
Diffuse panbronchiolitis is a progressive inflammatory disorder of the airways found almost exclusively in Japan. Clinically it is characterized by chronic cough, excessive sputum production, exertional breathlessness, chronic sinusitis and Pseudomonas colonization [121]. Untreated, the prognosis of diffuse panbronchiolitis is poor, with progressive deterioration of lung function, the development of diffuse bronchiectasis and death caused by respiratory failure. The introduction of long-term macrolide therapy has resulted in dramatic improvements in survival, with 5-year survival rates increasing from 63 to 92% [121, 122]. Significant symptom reduction and improved pulmonary function have also been achieved [123-126]. Also in patients with cystic fibrosis (CF) who are colonized with
7.5.3. Antimicrobial resistance
Giving long term antibiotic treatment to a patient may have consequences; the development of antimicrobial resistance is by far the most important one. Several researches have shown that the erm(B) and mef genes are mostly responsible for macrolide resistance in streptococci bacteria [139-142]. This resistance can develop even when short term therapy with macrolides is given [141]. The participants receiving azithromycin in the USA study, where a 1-year therapy was administered, were less likely to be colonized with respiratory pathogens but more likely to become colonized with macrolide resistant pathogens [138]. In the UK study in patients with COPD the researchers found there were no significant changes in resistance of sputum pathogens (
References
- 1.
COPD exacerbations: the importance of a standard definition. Respir Med,Pauwels R et al 2004 99 107 - 2.
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med,Rabe K. F et al 2007 532 555 - 3.
Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med,Seemungal T. A et al 1998 Pt 1):1418 1422 - 4.
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax,Donaldson G. C et al 2002 847 852 - 5.
Comorbidity, hospitalization, and mortality in COPD: results from a longitudinal study. Lung,Terzano C et al 2010 321 329 - 6.
Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med, Jr.,Connors A. F et al 1996 Pt 1):959 967 - 7.
Fat D, Global Burden of Disease: 2004 update,Mathers C B. T Ma 2008 World Health Organization.146 - 8.
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (revised 2011),Vestbo J 2011 Global Initiative for Chronic Obstructive Lung Disease.78 - 9.
Worldwide burden of COPD in high- and low-income countries. Part I. The burden of obstructive lung disease (BOLD) initiative. Int J Tuberc Lung Dis,Buist A. S andW. M Vollmer M. A Mcburnie 2008 703 708 - 10.
Chronic obstructive pulmonary disease in non-smokers. Lancet, andSalvi S. S P. J Barnes 2009 733 743 - 11.
Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review. BMC Med,Atsou K andC Chouaid G Hejblum 2011 7 - 12.
Epidemiology of chronic obstructive pulmonary disease: a literature review. Int J Chron Obstruct Pulmon Dis,Rycroft C. E et al 2012 457 494 - 13.
Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med,Langsetmo L et al 2008 396 401 - 14.
Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med,Seemungal T. A et al 2000 1608 1613 - 15.
Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. Eur Respir J,Jenkins C. R et al 2012 38 45 - 16.
Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med,Hurst J. R et al 2009 369 374 - 17.
Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med,Hurst J. R et al 2010 1128 1138 - 18.
Depression, but not sleep disorder, is an independent factor affecting exacerbations and hospitalization in patients with chronic obstructive pulmonary disease. Respirology,Ito K et al 2012 940 949 - 19.
The impact of depressive symptoms on recovery and outcome of hospitalised COPD exacerbations. Eur Respir J,Papaioannou A. I et al 2012 - 20.
Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med,Cosio M. G andM Saetta A Agusti 2009 2445 2454 - 21.
Innate immune responses are increased in chronic obstructive pulmonary disease. PLoS One,Baines K. J andJ. L Simpson P. G Gibson 2011 e18426 - 22.
The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med,Hogg J. C et al 2004 2645 2653 - 23.
Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med,Keatings V. M et al 1996 530 534 - 24.
Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med, andSethi S T. F Murphy 2008 2355 2365 - 25.
Effect of Bronchial Colonisation on Airway and Systemic Inflammation in Stable COPD. COPD,Marin A et al 2012 - 26.
Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest,Wilkinson T. M et al 2006 317 324 - 27.
Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med,Papi A et al 2006 1114 1121 - 28.
Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax,Bhowmik A et al 2000 114 120 - 29.
Nitrosative stress, heme oxygenase-1 expression and airway inflammation during severe exacerbations of COPD. Chest,Tsoumakidou M et al 2005 1911 1918 - 30.
Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med,Hurst J. R et al 2006 71 78 - 31.
Markers of inflammation and oxidative stress in exacerbated chronic obstructive pulmonary disease patients. Respir Med,Gerritsen W. B et al 2005 84 90 - 32.
Therapeutic blockade of interleukin-6 in chronic inflammatory disease. Clin Pharmacol Ther, andYamamoto K S Rose-john 2012 574 576 - 33.
Cytokines in chronic obstructive pulmonary disease. Eur Respir J Suppl,Chung K. F 2001 50s 59s - 34.
Interleukin-8 induces neutrophil transendothelial migration. Immunology,Smith W. B et al 1991 65 72 - 35.
Systemic inflammation and comorbidity in COPD: a result of’overspill’ of inflammatory mediators from the lungs? Review of the evidence. Thorax, andSinden N. J R. A Stockley 2010 930 936 - 36.
Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am J Respir Crit Care Med,Dekhuijzen P. N et al 1996 Pt 1):813 816 - 37.
Exhaled eicosanoids and biomarkers of oxidative stress in exacerbation of chronic obstructive pulmonary disease. Arch Med Sci,Antczak A et al 2012 277 285 - 38.
Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax,Biernacki W. A andS. A Kharitonov P. J Barnes 2003 294 298 - 39.
Decreased haem oxygenase-1 and increased inducible nitric oxide synthase in the lung of severe COPD patients. Eur Respir J,Maestrelli P et al 2003 971 976 - 40.
Increased expression of heme oxygenase (HO)-1 in alveolar spaces and HO-2 in alveolar walls of smokers. Am J Respir Crit Care Med,Maestrelli P et al 2001 Pt 1):1508 1513 - 41.
COPD exacerbations. 2: aetiology. Thorax, andSapey E R. A Stockley 2006 250 258 - 42.
COPD exacerbations: defining their cause and prevention. Lancet, andWedzicha J. A T. A Seemungal 2007 786 796 - 43.
Seasonality of viral infections: mechanisms and unknowns. Clin Microbiol Infect,Fisman D 2012 946 954 - 44.
Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med,Mallia P et al 2011 734 742 - 45.
Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med,Seemungal T et al 2001 1618 1623 - 46.
Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax,Rohde G et al 2003 37 42 - 47.
Viral etiology of acute exacerbations of COPD in Hong Kong. Chest,Ko F. W et al 2007 900 908 - 48.
A 1-year prospective study of the infectious etiology in patients hospitalized with acute exacerbations of COPD. Chest,Ko F. W et al 2007 44 52 - 49.
Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med,Bafadhel M et al 2011 662 671 - 50.
Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am J Respir Crit Care Med,Sethi S et al 2006 991 998 - 51.
Relevance of lower airway bacterial colonization, airway inflammation, and pulmonary function in the stable stage of chronic obstructive pulmonary disease. Eur J Clin Microbiol Infect Dis,Zhang M et al 2010 1487 1493 - 52.
New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med,Sethi S et al 2002 465 471 - 53.
Temporal relationship between air pollutants and hospital admissions for chronic obstructive pulmonary disease in Hong Kong. Thorax,Ko F. W et al 2007 780 705 - 54.
Ambient air pollution particles and the acute exacerbation of chronic obstructive pulmonary disease. Inhal Toxicol,Sint T andJ. F Donohue A. J Ghio 2008 25 29 - 55.
Effects of coarse particulate matter on emergency hospital admissions for respiratory diseases: a time-series analysis in Hong Kong. Environ Health Perspect,Qiu H et al 2012 572 576 - 56.
Airborne particulate matter and human health: toxicological assessment and importance of size and composition of particles for oxidative damage and carcinogenic mechanisms. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev,Valavanidis A andK Fiotakis T Vlachogianni 2008 339 362 - 57.
Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest,Stockley R. A et al 2000 1638 1645 - 58.
Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J,Perera W. R et al 2007 527 534 - 59.
Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One,Agusti A et al 2012 e37483 - 60.
In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue. Endocrinology,Linscheid P et al 2003 5578 5584 - 61.
Role of procalcitonin in managing adult patients with respiratory tract infections. Chest,Schuetz P andD. N Amin J. L Greenwald 2012 1063 1073 - 62.
Procalcitonin-guided antibiotic therapy for chronic obstructive pulmonary disease exacerbations. Expert Rev Anti Infect Ther,Tokman S andP Schuetz S Bent 2011 727 735 - 63.
Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA,Schuetz P et al 2009 1059 1066 - 64.
Resistance training prevents deterioration in quadriceps muscle function during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med,Troosters T et al 2010 1072 1077 - 65.
Exercise training improves recovery in patients with COPD after an acute exacerbation. Respir Med,Kirsten D. K et al 1998 1191 1118 - 66.
Effects of an acute exacerbation on nutritional and metabolic profile of patients with COPD. Eur Respir J,Vermeeren M. A andA. M Schols E. F Wouters 1997 2264 2269 - 67.
Nutritional support in patients with chronic obstructive pulmonary disease during hospitalization for an acute exacerbation; a randomized controlled feasibility trial. Clin Nutr,Vermeeren M. A et al 2004 1184 1192 - 68.
Impact of nutritional support on functional status during an acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med,Saudny-unterberger H andJ. G Martin K Gray-donald 1997 Pt 1):794 799 - 69.
Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study. Chest,De Jong Y. P et al 2007 1741 1747 - 70.
Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med,Anthonisen N. R et al 1987 196 204 - 71.
Sputum purulence-guided antibiotic use in hospitalised patients with exacerbations of COPD. Eur Respir J,Soler N et al 2012 - 72.
Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med,Daniels J. M et al 2010 150 157 - 73.
Efficacy of Antibiotic Therapy for Acute Exacerbations of Mild to Moderate COPD. Am J Respir Crit Care Med,Llor C et al 2012 - 74.
Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev,Puhan M. A et al 2011 CD005305 - 75.
A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest,Donohue J. F et al 2002 47 55 - 76.
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J,Casaburi R et al 2002 217 224 - 77.
A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med,Tashkin D. P et al 2008 1543 1554 - 78.
Long-term safety and efficacy of indacaterol, a long-acting beta(2)-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest,Chapman K. R et al 2011 68 75 - 79.
Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax,Stockley R. A andN Chopra L Rice 2006 122 128 - 80.
Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease. Drugs,Mckeage K 2012 543 563 - 81.
Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med,Donohue J. F et al 2010 155 162 - 82.
Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax,Dahl R et al 2010 473 479 - 83.
Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res, A.,D Urzo et al 2011 156 - 84.
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J,Kerwin E et al 2012 1106 1114 - 85.
QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax,Van Noord J. A et al 2010 1086 1091 - 86.
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med,Calverley P. M et al 2007 775 789 - 87.
The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med,Wedzicha J. A et al 2008 19 26 - 88.
Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J,Jones P. W et al 2003 68 73 - 89.
Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology,Zhou Y et al 2006 603 610 - 90.
Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest,Rossi A et al 2002 1058 1069 - 91.
ZuWallack R.L., et al., Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest,2001 1661 1670 - 92.
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet,Calverley P. M et al 2009 685 694 - 93.
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet,Fabbri L. M et al 2009 695 703 - 94.
Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother,Retsema J et al 1987 1939 1947 - 95.
Comparison of macrolide antibiotics. J Antimicrob Chemother, andWilliams J. D A. M Sefton 1993 Suppl C:11 26 - 96.
Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. Antimicrob Agents Chemother,Bosnar M et al 2005 2372 2377 - 97.
and G. Gialdroni Grassi, Requirements for intracellular accumulation and release of clarithromycin and azithromycin by human phagocytes. J Chemother,Fietta A C Merlini 1997 23 31 - 98.
The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother,Foulds G andR. M Shepard R. B Johnson 1990 Suppl A:73 82 - 99.
Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob Agents Chemother,Girard A. E et al 1987 1948 1954 - 100.
Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa. Antimicrob Agents Chemother,Mizukane R et al 1994 528 533 - 101.
The in vitro effect of macrolides on the interaction of human polymorphonuclear leukocytes with Pseudomonas aeruginosa in biofilm. Chemotherapy,Takeoka K et al 1998 190 197 - 102.
Potential of macrolide antibiotics to inhibit protein synthesis of Pseudomonas aeruginosa: suppression of virulence factors and stress response. J Infect Chemother,Tateda K et al 2000 1 7 - 103.
Postantibiotic suppression effect of macrolides on the expression of flagellin in Pseudomonas aeruginosa and Proteus mirabilis. J Infect Chemother,Kawamura-sato K et al 2001 51 54 - 104.
Azithromycin inhibits the formation of flagellar filaments without suppressing flagellin synthesis in Salmonella enterica serovar typhimurium. Antimicrob Agents Chemother,Matsui H et al 2005 3396 3403 - 105.
Interaction between clarithromycin and biofilms formed by Staphylococcus epidermidis. Antimicrob Agents Chemother,Yasuda H et al 1994 138 141 - 106.
Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms. Antimicrob Agents Chemother,Starner T. D et al 2008 137 145 - 107.
The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. Chemotherapy,Ichimiya T et al 1996 186 191 - 108.
Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother,Skindersoe M. E et al 2008 3648 3663 - 109.
Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J Antimicrob Chemother,Molinari G et al 1993 681 688 - 110.
Therapeutic effect of erythromycin on influenza virus-induced lung injury in mice. Am J Respir Crit Care Med,Sato K et al 1998 Pt 1):853 857 - 111.
Erythromycin inhibits rhinovirus infection in cultured human tracheal epithelial cells. Am J Respir Crit Care Med,Suzuki T et al 2002 1113 1118 - 112.
Clarithromycin inhibits type a seasonal influenza virus infection in human airway epithelial cells. J Pharmacol Exp Ther,Yamaya M et al 2010 81 90 - 113.
Erythromycin and common cold in COPD. Chest,Suzuki T et al 2001 730 733 - 114.
Azithromycin maintains airway epithelial integrity during Pseudomonas aeruginosa infection. Am J Respir Cell Mol Biol,Halldorsson S et al 2010 62 68 - 115.
Novel effects of azithromycin on tight junction proteins in human airway epithelia. Antimicrob Agents Chemother,Asgrimsson V et al 2006 1805 1812 - 116.
Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. Am J Respir Crit Care Med,Hodge S et al 2008 139 148 - 117.
Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages. Eur Respir J,Hodge S et al 2006 486 495 - 118.
Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol,Culic O et al 2002 277 289 - 119.
Macrolide antibiotics broadly and distinctively inhibit cytokine and chemokine production by COPD sputum cells in vitro. Pharmacol Res,Marjanovic N et al 2011 389 397 - 120.
Azithromycin inhibits mucus hypersecretion from airway epithelial cells. Mediators Inflamm, 2012. andShimizu T S Shimizu 2012 265714 - 121.
Applying lessons learned in the treatment of diffuse panbronchiolitis to other chronic inflammatory diseases. Am J Med,Kudoh S 2004 Suppl 9A:12S 19S - 122.
Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med,Kudoh S et al 1998 Pt 1):1829 1832 - 123.
Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Thorax,Fujii T et al 1995 1246 1252 - 124.
Reversible airway lesions in diffuse panbronchiolitis. Detection by high-resolution computed tomography. Chest,Ichikawa Y et al 1995 120 125 - 125.
Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respir Med,Kadota J et al 2003 844 850 - 126.
Effect of 14-membered ring macrolide therapy on chronic respiratory tract infections and polymorphonuclear leukocyte activity. Intern Med,Shirai T andA Sato K Chida 1995 469 474 - 127.
Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial. Thorax,Clement A et al 2006 895 902 - 128.
Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J Cyst Fibros,Hansen C. R et al 2005 35 40 - 129.
Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA,Saiman L et al 2003 1749 1756 - 130.
Improved lung function and body mass index associated with long-term use of Macrolide antibiotics. J Cyst Fibros,Pirzada O. M et al 2003 69 71 - 131.
Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet,Equi A et al 2002 978 984 - 132.
Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax,Wolter J et al 2002 212 216 - 133.
Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev,Southern K. W andP. M Barker A Solis 2004 CD002203 - 134.
Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet,Wong C et al 2012 660 667 - 135.
Long term azithromycin treatment: A randomised placebo-controlled trial in non-CF bronchiectasis; results from the BAT trial in European Respiratory Society CongressAltenburg J De Graaff C Van Der Werf T Boersma W 2011 Amsterdam. - 136.
The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respir Med,Banerjee D andO. A Khair D Honeybourne 2005 208 215 - 137.
Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med,Seemungal T. A et al 2008 1139 1147 - 138.
Azithromycin for Prevention of Exacerbations of COPD. N Engl J Med,Albert R. K et al 2011 689 698 - 139.
Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995. Clin Infect Dis,Shortridge V. D et al 1999 1186 1188 - 140.
Emergence and persistence of macrolide resistance in oropharyngeal flora and elimination of nasal carriage of Staphylococcus aureus after therapy with slow-release clarithromycin: a randomized, double-blind, placebo-controlled study. Antimicrob Agents Chemother,Berg H. F et al 2004 4183 4188 - 141.
Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet,Malhotra-kumar S et al 2007 482 490 - 142.
Resistance to macrolides and related antibiotics in Streptococcus pneumoniae. Antimicrob Agents Chemother, andLeclercq R P Courvalin 2002 2727 2734 - 143.
Hidden epidemic of macrolide-resistant pneumococci. Emerg Infect Dis, andKlugman K. P J. R Lonks 2005 802 807 - 144.
Meta-analysis of bacterial resistance to macrolides. J Antimicrob Chemother,Halpern M. T et al 2005 748 757